TORONTO, Jan. 30, 2013 /CNW/ - BIOSENTA INC. (CNSX: ZRO) (the "Company") is pleased to announce a private placement of up to
4,000,000 units at a price of $0.15 per unit for gross proceeds of up
to $600,000 (the "Offering"). Each unit consists of one Class A Share
and one-half of one Class A Share purchase warrant. Each whole warrant
will entitle the holder to purchase one additional Class A Share in the
capital of the Corporation (a "Warrant Share") at an exercise price of
$0.20 per Warrant Share to the extent such Warrant is exercised on or
before the date that is 18 months from the closing date of the
Offering. The Company may pay a finder's fee consisting of 8% cash
and warrants to acquire Class A Shares at $0.20 per Class A Share
exercisable during the period up to 18 months following closing of the
Offering. The number of Warrants to be issued will equal to 8% of the
number Units sold in the Offering. All securities issued will be
subject to a four-month hold period. The proceeds will be used for
working capital purposes and in furtherance of the Company's activities
in connection with development of product lines, including development
of its pilot plant and research facility Parry Sound, Ontario.
About BIOSENTA Inc.
BIOSENTA Inc.'s line of retail anti-microbial products will effectively
kill mold, bacteria and fungi on contact and prevent re-growth. These
products address the demand created by the mounting health and
environmental concerns. Mold can affect the immune system, nervous
system, liver, kidneys, blood and cause brain damage.
BIOSENTA will also manufacture and distribute an anti-microbial filler.
Calcium Carbonate is one of the most common fillers used industrially.
It is susceptible like other fillers that hold moisture to attracting
mold. Annual global revenue in the calcium carbonate filler industry
approximates 140 billion dollars. BIOSENTA will produce anti-microbial
filler that performs 'filling' and 'bulking' functions like calcium
carbonate. BIOSENTA's filler product will not attract moisture and
consequently mold infestation. BIOSENTA's filler with its
anti-microbial high ph core in individual particles will enhance
commercial product life and eradicate a broad spectrum of known
bacteria, fungi, algae and other micro-organisms by suppression of
This release may contain forward-looking statements information and
statements which constitute "forward-looking information" under
Canadian securities law and which may be material regarding, among
other things, the Company's beliefs, plans, objectives, estimates,
intentions and expectations with respect to its capital and funding
plans. Inherent in the forward-looking information and statements are
known and unknown risks, uncertainties and other factors beyond the
Company's ability to control or predict, which give rise to the
possibility that the Company's predictions, forecasts, expectations or
conclusions will not prove to be accurate, that its assumptions may not
be correct and that the Company's plans, objectives and statements will
not be achieved. Actual results or developments may differ materially
from those contemplated by the forward-looking information and
statements. Consequently, undue reliance should not placed on such
On behalf of the Board of Directors of BIOSENTA Inc.
The CNSX has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved of the contents of
this press release. Neither the CNSX nor its Regulation Services
Provider (as such term is defined in the policies of the CNSX) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: BIOSENTA Inc.
For further information:
Bruce Lewis, President & Chief Executive Officer
1120 Finch Avenue West, Suite 503,
Toronto, Ontario M3J 3H7
(416) 410 2019